يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Domingo‐García, Abel"', وقت الاستعلام: 0.45s تنقيح النتائج
  1. 1
    Academic Journal
    Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.

    المؤلفون: García-Muñoz, Ricardo, Quero, Cristina, Pérez-Persona, Ernesto, Domingo-García, Abel, Pérez-López, Cristina, Villaescusa-de-la-Rosa, Teresa, Martínez-Castro, Ana M, Arguiñano-Pérez, José M, Parra-Cuadrado, Juan F, Panizo, Carlos

    مصطلحات موضوعية: administration-related reactions, follicular lymphoma, non-Hodgkin diffuse large B-cell lymphoma, rituximab, safety, Administration, Intravenous, Adolescent, Adult, Aged, 80 and over, Disease-Free Survival, Female, Humans, Infusions, Subcutaneous, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Quality of Life, Spain, Survival Rate

    وصف الملف: application/pdf

    Relation: http://hdl.handle.net/10668/14571; PMC7065214; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065214/pdf

    الاتاحة: http://hdl.handle.net/10668/14571
    https://doi.org/10.1111/bjh.16227
    https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16227
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065214/pdf

    View record in BASE

    أضف إلى المفضلة
  2. 2
    Academic Journal
    Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study.

    المؤلفون: Tamayo, Rafael Ríos, Herraiz, Mario Arnao, domingo garcía, abel, Sanchez-Majano Suarez-Llanos, Jose Luis, Soler, Juan Alfons, Guiñon, Antonio Garcia, Lopez, Sebastian Garzon, Guia, Ana, Farre, Carolina Leiva, Pardo, Miriam Gonzalez, Rubia, Javier DE.LA., Mateos, Maria-Victoria

    المصدر: Clinical Lymphoma Myeloma and Leukemia ; volume 19, issue 10, page e147 ; ISSN 2152-2650

    الاتاحة: http://dx.doi.org/10.1016/j.clml.2019.09.245
    https://api.elsevier.com/content/article/PII:S2152265019316325?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S2152265019316325?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  3. 3
    Academic Journal
    Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study.

    المؤلفون: García‐Muñoz, Ricardo, Quero, Cristina, Pérez‐Persona, Ernesto, Domingo‐García, Abel, Pérez‐López, Cristina, Villaescusa‐de‐la‐Rosa, Teresa, Martínez‐Castro, Ana M., Arguiñano‐Pérez, José M., Parra‐Cuadrado, Juan F., Panizo, Carlos

    المصدر: British Journal of Haematology; Mar2020, Vol. 188 Issue 5, p661-673, 13p, 1 Diagram, 6 Charts, 1 Graph

    مصطلحات موضوعية: RITUXIMAB, NON-Hodgkin's lymphoma, INTRAVENOUS therapy, MEDICAL care surveys


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء